Tempus AI logo
Tempus AI
TEM | NASDAQ
Chart Builder DCF Calculator
$64.76
-$6.84 (-9.55%)
At close: Nov 16, 2026, 4:00 PM ET
$66.85
+$2.09 (+3.23%)
After-hours: Nov 16, 2026, 7:59 PM ET

Tempus AI Company Profile

Company profile explained

Company Profile

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Key Executives

Name Position
Eric Lefkofsky Co-Founder, Chief Executive Officer, President & Chairman
Ryan Fukushima Chief Executive Officer of Data & Apps
Andrew Polovin Chief Legal Officer
James Rogers Chief Financial Officer
Shane Colley Chief Technology Officer
Stacey Kraft Chief People Officer
Christina Antoniou Senior Vice President & Head of Corporate Development
Elizabeth Krutoholow Vice President of Investor Relations & Competitive Intelligence
Erik Phelps Executive VP and Chief Administrative & Legal Officer
Kate A. Sasser Chief Scientific Officer
Ryan Bartolucci Chief Accounting Officer

Latest SEC Filings

Date Type Title
Oct 29, 2026 4 Filing
Oct 28, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 23, 2026 8-K Current Report
Oct 21, 2026 EFFECT Filing
Oct 21, 2026 424B3 Filing
Oct 20, 2026 S-4/A [Amend] Filing
Oct 02, 2026 S-4/A [Amend] Filing
Sep 29, 2026 4 Filing
Sep 24, 2026 4 Filing
Sep 18, 2026 4 Filing
View All SEC Filings ➞
Tempus AI
Tempus AI logo
Country United States
IPO Date Jun 14, 2024
Industry Medical - Healthcare Information Services
Sector Healthcare
Employees 3,800
CEO Eric Lefkofsky

Contact Details

600 West Chicago Avenue Chicago, Illinois 60654 United States

Stock Details

Ticker Symbol TEM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001717115
CUSIP Number 88023B103
ISIN Number US88023B1035
SIC Code 7370

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.